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Background: The marked improvement in outcome following induction of hypothermia after cardiac arrest has
spurred the search for better methods to induce cooling. A regulated decrease in core temperature mediated by a
drug-induced reduction in the set point for thermoregulation may be an ideal means of inducing hypothermia.
To this end, the exploratory drug HBN-1 was assessed as a means to induce mild and prolonged hypothermia.
Methods: Free moving rats were infused i.v. for 12 hours with: a vehicle at room temperature (normothermia), a
vehicle chilled to 4C (forced hypothermia), or HBN-1 (mixture of ethanol, lidocaine, and vasopressin) at room
temperature. Core (intra-abdominal) temperature (Tc) was measured telemetrically, tail skin temperature (Ttail)
by infrared thermography, metabolic rate (MR) was estimated with indirect calorimetery, and shivering was
scored visually.
Results: HBN-1 elicited a reduction in Tc from 37.5C to 34C within 80 minutes after initiation of the infusion; Tc
was maintained between 33C and 34C for more than 13 hours. HBN-1 infusion was associated with a re-
duction in MR ( p = 0.0006), a slight reduction in Ttail, and no evidence of shivering ( p < 0.001). The forced
hypothermia group displayed shivering ( p < 0.001), a significant increase in MR, and a decrease in Ttail, indic-
ative of peripheral vasoconstriction to reduce heat loss.
Conclusion: HBN-1 infusion induced a mild and prolonged hypothermia in free moving, unanesthetized rats
characterized by modulation of thermoeffectors to reduce heat gain and increase heat loss. HBN-1 thus appears
to elicit regulated hypothermia and may provide a new method for achieving a prolonged state of therapeutic
hypothermia.
Introduction
There is strong evidence that prolonged, mild hypo-thermia protects the brain from acute ischemic injury
(Dietrich et al., 1994; Bernard et al., 2002; Hemmen and Lyden,
2009). However, there has been slow acceptance of hypo-
thermia in clinical practice because the current methods of
cooling are complex and potentially dangerous to overall
patient outcome (Abella et al., 2005; Merchant et al., 2006). The
current methods for cooling are physical and include ice bags,
cooling pads, and endovascular devices that forcefully lower
body temperature. These forced physical methods alone are
inefficient and stressful in lowering body temperature be-
cause of the thermoregulatory system’s vigorous response to
hypothermia; any attempts to cool the body are met with
peripheral vasoconstriction to reduce cutaneous heat loss and
shivering to increase heat production (Frank et al., 1997). As a
result, narcotics with or without skeletal muscle relaxing
agents must be given before initiation of forced cooling, and
these drugs can cause hypotension and respiratory arrest that
require mechanical ventilation (Sessler, 2009). Forced cooling
is stressful to multiple physiological systems, and patients
may experience thermal discomfort. In addition, these forced
cooling methods and drugs are not readily available on am-
bulances. Patients must wait minutes or even hours before
cooling is initiated in hospital, thus delaying the time for
reaching therapeutic hypothermia and reducing the efficacy
of cooling (Kuboyama et al., 1993; Wolff et al., 2009).
Over the past several years, our laboratory has been de-
veloping an injectable drug that can quickly lower body
temperature to a therapeutic level of *34C and maintain
body temperature at this level for at least 12 hours to assure an
effective state of hypothermia. HBN-1 is a combination of
commercially available drugs including ethanol, vasopressin,
and lidocaine. Ethanol lowers the thermoregulatory set-point
and elicits a regulated hypothermia in rodents (Gordon and
Stead, 1986). The toxicity, safety margin, and pharmacology
of ethanol in humans and test species are well known. Recent
human studies have shown that ethanol elicits a heat
dissipating response, characterized by sweating, peripheral
1University of North Carolina School of Medicine, Chapel Hill, North Carolina.
2Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, Alabama.
3U.S. Environmental Protection Agency, Neurotoxicology, Research Triangle Park, North Carolina.
THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT
Volume 2, Number 2, 2012
ª Mary Ann Liebert, Inc.
DOI: 10.1089/ther.2012.0011
61
vasodilation, and preference for cool ambient temperatures
(Yoda et al., 2005). But ethanol alone is unable to sustain a
long-term hypothermia because tolerance develops rapidly
(Froehlich et al., 2001). Vasopressin and lidocaine may reduce
tolerance to ethanol-induced hypothermia (Alfonsi et al., 1995;
Daikoku et al., 2007). Therefore, vasopressin and lidocaine were
combined with ethanol to prepare the HBN-1 with the objective
of inducing and prolonging hypothermia. The aim of this ex-
ploratory study was to evaluate if intravenous HBN-1 elicits
the desired regulated hypothermic response in free-moving
rats by modulating the thermoeffectors for heat gain (shiver-
ing/metabolism) and heat loss (peripheral vasomotor tone) to
induce controlled and prolonged mild hypothermia.
Methods
Experiments were approved by the Institutional Animal
Care and Use Committee and adhered to NIH guidelines for
the ethical treatment of animals. Rats under titrated inhaled
isoflurane anesthesia were implanted with intraabdominal
telemetric temperature probes (MiniMitter, Bend, OR) and
tunneled intravenous femoral venous catheters (PE 50 tub-
ing). Anesthesia was discontinued for 3 hours before thera-
peutic interventions were initiated.
HBN-1 is a premixed combination of 63 g/L of ethanol,
2.7 U/L of vasopressin, and 66 mg/L of lidocaine. The rate
and volume of the HBN bolus was chosen to be comparable to
the rate and volume of iced saline bolus given to patients after
resuscitation from cardiac arrest for possible future compar-
isons (Bernard et al., 2003; Moore et al., 2008). The work of
Lomax provided guidance on the dosing of ethanol required
initially to lower core (intra-abdominal) temperature by 2–4C
(Lomax et al., 1980). The dose of vasopressin and lidocaine to
maintain hypothermia with ethanol was based on prelimi-
nary dose finding studies.
Thirty rats were randomized before surgical preparation to
one of three groups; (1) normothermia, (2) forced hypother-
mia, or (3) HBN-1. Three rats from the normothermia group,
three rats from the forced hypothermia group, and two rats
from the HBN-1 group were prospectively excluded from
analysis due to complications during surgical preparation.
Normothermia rats (n = 7) received an intravenous bolus of
30 mL/kg of normal saline vehicle over 30 minutes followed
by a 3 mL/kg/h infusion for 12 hours. The temperature of the
injectate was equilibrated to room temperature. The normo-
thermia rats were maintained in a 19C environment for the
entire 1200-minute experiment. Forced hypothermia rats re-
ceived a 30 mL/kg intravenous bolus of chilled (4C) vehicle
over 30 minutes followed by a 3 mL/kg/h chilled infusion for
12 hours. The forced hypothermia rats (n = 7) were initially
maintained at an environmental temperature of 4C for 1 hour
and then maintained at 19C for the remainder of the 1200
minutes. The HBN-1 group (n = 8) received a 30 mL/kg bolus of
premixed solution (total dose: 1.89 g/kg of ethanol, 0.08 U/kg of
vasopressin, 2 mg/kg of lidocaine) over 30 minutes in an envi-
ronmental temperature of 19C followed by 3 mL/kg/h infu-
sion for 12 hours (total dose: 2.27 g/kg of ethanol, 0.096 U/kg of
vasopressin, and 2.4 mg/kg of lidocaine) at the same environ-
mental temperature. The temperature of the HBN-1 was equil-
ibrated to room temperature (19C).
Intra-abdominal temperature, defined as the core temper-
ature of the rat, was measured every 10 minutes with the
surgically implanted intra-abdominal telemetric temperature
probe for approximately 1200 minutes. Tail temperature was
measured by infrared thermography (IRCameras, Walpole,
MA) every 10 minutes for the first 120 minutes of infusions.
Infrared images were analyzed using Thermography Suite
software (IRCameras, Walpole, MA), which measured the
mean surface temperature of the proximal 1 cm of tail. During
infusion, rats were housed in a clear acrylic box (21 cm ·
22 cm · 12 cm); respiratory gases were extracted and con-
verted to metabolic rate using the principle of open circuit
respirometry (Fox Box and Gas Dryer ND-2, Sable Systems
International, Las Vegas, NV). Rats were allowed to acclimate
for 3 hours in the metabolic chamber after discontinuation of
isoflurane before measurements were obtained. Oxygen
consumption and carbon dioxide production were obtained
every 10 minutes for the first 120 minutes of infusion, and
metabolic rate was estimated using the formula VO2 = flow
rate · [(FiO2 - FeO2) - FiO2 · (FeCO2 - FiCO2)]/(1 - FiO2)
according to the manufacturer’s recommendation. A piece of
transparent plastic with a small opening to allow introduction
of the femoral venous line was placed over the chamber. The
plastic allowed for IR measurement of tail temperature.
Outcome parameters included core temperature, metabolic
rate, tail temperature, and incidence of shivering. Shivering
was defined as any involuntary high frequency contraction of
trunk muscles and was continuously monitored during the
first 120 minutes of infusions. All analyses were performed by
an observer blinded to interventions.
Statistical Analysis
A hierarchical linear model (HLM; also often referred to as
a mixed model or a random effects model) was used to
evaluate the association between the treatment groups and
outcome measures of interest (e.g., metabolism) over time.
HLMs are used to account for the repeated measurements
taken on a single study participant over time and have a
number of advantages over traditional techniques, including
the ability to incorporate incomplete (i.e., missing) data. When
appropriate, a quadratic parameter for time was also included
to improve the model fit. Shivering was dichotomized into
any versus none and analyzed using logistic regression.
P-values ofp0.05 (two-sided) were considered statistically
significant. All statistical analyses were performed using SAS,
v. 9.3 (SAS Institute, Cary, NC).
Results
Administration of the vehicle to the normothermic group
had essentially no effect on core temperature (Fig. 1). It re-
mained at approximately 37C and increased to around 38C
overnight (Fig. 2). Administration of the iced vehicle to the
forced hypothermia group also had no remarkable effects on
core temperature. In fact, core temperature increased slightly
above the normothermic group and remained elevated as
much as 1C over the 12-hour infusion period. Infusion of
HBN-1 led to a precipitous fall in core temperature, decreas-
ing from 37.5C to 34C in a mean and standard deviation of
80 – 78 minutes (Fig. 1). The rats were free moving, eating,
grooming, and did not appear grossly sedated. The rats also
did not exhibit behavior that would be characteristic of cold
stress such as shivering. As infusion of HBN-1 progressed,
core temperature decreased gradually, reaching a nadir of
62 KATZ ET AL.
33C at around 600 minutes (Fig. 2). There was a stabilization
of core temperature in the HBN-1 group in spite of continuous
HBN-1 infusion. Overall, core temperature of this group re-
mained below 34C for an average of 13.3 – 5.6 hours. With
respect to core temperature, the HBN-1 group experienced a
statistically significant rapid and sustained decrease in core
temperature, whereas no such change was observed in the
forced hypothermia and normothermia groups ( p < 0.0001;
Fig. 1). The HBN-1 group maintained hypothermia for the
duration of the infusion (Fig. 2). Metabolic rate and tail skin
temperature during the first 30 minutes of infusion showed
significant differences depending on treatment (Figs. 3 and 4).
In our calculation of the change in metabolic rate, the forced
hypothermia group underwent a marked increase during the
FIG. 1. The mean body temperature in free-moving rats receiving vehicle (normothermia) in an environmental temperature
of 19C, iced saline in an environmental temperature of 4C (forced hypothermia), or HBN-1 in an environmental temper-
ature of 19C. The error bars represent standard deviations.
FIG. 2. The mean body temperature in free-moving rats receiving vehicle (normothermia) in an environmental temperature
of 19C, iced saline in an environmental temperature of 4C (forced hypothermia), or HBN-1 in an environmental temper-
ature of 19C.
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first 30 minutes of infusion ( p = 0.0118). In addition, vigorous
shivering was observed in the forced hypothermia group;
these animals typically assumed a ball-like shape as they ex-
hibited the involuntary, muscular contractions characteristic
of shivering. The lowest tail temperatures were observed in
the forced hypothermia group (both p < 0.0001). Metabolic
rate of the HBN-1 group decreased below that of the normo-
thermia group during the first hour of infusion ( p = 0.0002).
Tail skin temperature of the HBN-1 group was below that of
the normothermic group but above that of the forced hypo-
thermia group during the first hour of infusion ( p < 0.0001).
The HBN-1 and forced hypothermia groups experienced
FIG. 3. Change in metabolic rate compared to baseline in free-moving rats receiving vehicle (normothermia) in an envi-
ronmental temperature of 19C, iced saline in an environmental temperature of 4C (forced hypothermia), or HBN-1 in an
environmental temperature of 19C. The error bars represent standard deviations.
FIG. 4. The mean tail temperature measured by infrared thermography in free-moving rats receiving vehicle (normo-
thermia) in an environmental temperature of 19C, iced saline in an environmental temperature of 4C (forced hypothermia),
or HBN-1 in an environmental temperature of 19C. The error bars represent standard deviations.
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statistically significant reductions in tail temperature during
the first hour of infusion, while minimal change was observed
in the normothermia group ( p < 0.0001). Most importantly,
there was no evidence of shivering in the HBN-1 group
( p < 0.001) despite the marked decrease in core temperature.
Discussion
Intravenous infusion of HBN-1 induced a rapid reduction
in core temperature to a level that is considered therapeutic
for the treatment of CNS ischemic diseases (Logue et al., 2007).
Most importantly, the hypothermic response developed with
concomitant modulation of thermoregulatory motor outputs,
suggesting that HBN-1 induced a reduction in the set-point
for regulation of core temperature. As core temperature de-
creased to 34C, tail skin temperature decreased below that of
the normothermic group but did not decrease to the levels
seen in the forced hypothermia group, suggesting that tail
skin blood flow in the HBN-1 group was maintained at a
moderate level despite significant hypothermia. In addition,
the rats did not shiver nor show outward signs of cold stress
(e.g., body posture was not ball shaped) throughout the pe-
riod of HBN-1 infusion and their metabolic rate decreased
below that of the normothermic group, suggesting suppres-
sion in shivering and nonshivering thermogenesis. Following
the 30-minute initial period of HBN-1 bolus infusion, the
maintenance infusion was effective in maintaining hypo-
thermia for at least 12 hours. This period of mild hypothermia
produced by the HBN-1 infusion was of duration sufficient to
provide neurological protection after an acute brain injury, as
demonstrated in laboratory experiments and human clinical
trials (Bernard et al., 2002; Clark et al., 2008).
Rats maintain body temperature when placed in a cool
environment by shivering and nonshivering thermogenesis to
raise heat production and peripheral vasoconstriction of
blood to minimize heat loss (Gordon, 1993). Vasomotor con-
trol of blood flow to the tail is a critical means of controlling
heat loss in rats (Dawson and Keber, 1979). At a constant
ambient temperature, temperature of the tail is essentially
proportional to tail blood flow. A noninvasive measurement
of tail skin temperature by IR thermography is an ideal means
of estimating tail blood flow (Vianna and Carrive, 2005; Katz
et al., 2008).
The forced hypothermia experiment illustrates the vigorous
thermoregulatory response, including hypermetabolism, de-
creased tail temperature (indirect measure of vasoconstri-
ction), and shivering with posturing of the body in a ball shape
that a free-moving rat can mount when given a thermal chal-
lenge. There was minimal decrease in core temperature in the
forced hypothermia group despite rapid infusion of iced saline
while being exposed to an environmental temperature of 4C
during the first hour of infusion. Indeed, there was overcom-
pensation in the responses as evidence by the nearly 1C ele-
vation in core temperature of the forced hypothermia group
over the normothermia group. Indeed, unrestrained rats ex-
posed to cold temperatures may overcompensate and exhibit
an elevation in core temperature (Yang and Gordon, 1996).
The optimal method for inducing hypothermia to treat
acute brain ischemia has not been defined. Increased metab-
olism, vasoconstriction, shivering, and other stressors of
forced hypothermia may exacerbate acute brain ischemia and
delay the time to therapeutic hypothermia (Badjatia et al.,
2007; Kim et al., 2007) and limit the full neuroprotective po-
tential of hypothermia (Wolff et al., 2009). HBN-1 induced
regulated hypothermia may be a less stressful homeostatic
process and thus affords multiple advantages over conven-
tional forced cooling as a neuroprotectant therapy and de-
serves further evaluation in models of acute brain injury.
The individual drugs in HBN-1 are FDA approved and
used in clinical practice, but hold the potential for adverse
affects including sedation, respiratory depression, hyperten-
sion, hypotension, and lowering of the seizure threshold.
None of these adverse affects were noted during the study,
although blood pressure was not measured. However, the
safety profile of HBN-1, when administered in combination, is
necessary for further drug development before it can be
considered for use in ambulances and other clinical settings. A
dose response study will also be helpful for future study.
Limitations
HBN-1 was premixed and administered in a single syringe,
so it was not possible to evaluate the contributions of the
individual components of HBN-1 on thermoregulation or
why the combination of drugs reduced the hypothermia tol-
erance observed with ethanol alone (Froehlich et al., 2001).
Past studies suggest that single injections of lidocaine or va-
sopressin would not have the effects on body temperature as
seen with HBN-1 (Banet and Wieland, 1985; Harris et al.,
1989). Nonetheless, future studies evaluating the individual
components of HBN-1 are needed to provide an under-
standing of the mechanisms by which the combination ther-
apy is able to provide rapid and prolonged lowering of body
temperature without need for anesthesia or paralysis. No di-
rect measures of tail blood flow or heat exchange were per-
formed in this study. However, previous work has validated
the usefulness of infrared imaging to predict reduction in tail
blood flow, and reduced tail blood flow has been associated
with preservation of body temperature (Dawson and Keber,
1979; Vianna and Carrive, 2005). Since brain temperature was
not measured, it can only be assumed that core temperature
reflects a change in brain temperature. Another limitation of
this study is how the observations in rats will extend to other
species. HBN-1 modulated the multiple thermoeffectors used
by most mammals to lower body temperature, but studies in
other species are needed to evaluate the translational value of
HBN-1 to lower body temperature.
Conclusions
HBN-1 infusion induced a mild and prolonged hypother-
mia in free moving, unanesthetized rats maintained at room
temperature (19C). HBN-1 appears to elicit a state of regu-
lated hypothermia and may provide a new method for in-
ducing therapeutic hypothermia.
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